The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to
rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients.
It is a multicenter, randomized, open, parallel, active-controlled, non-inferiority trial.
Phase:
Phase 4
Details
Lead Sponsor:
Guangzhou Recomgen Biotech Co., Ltd.
Collaborators:
Chinese Academy of Medical Sciences, Fuwai Hospital Peking University